An Updated Meta-Analysis of Endothelial Nitric Oxide Synthase Gene: Three Well-Characterized Polymorphisms with Hypertension by Niu, Wenquan & Qi, Yue
An Updated Meta-Analysis of Endothelial Nitric Oxide
Synthase Gene: Three Well-Characterized
Polymorphisms with Hypertension
Wenquan Niu
1,2,3*,Y u eQ i
4*
1State Key Laboratory of Medical Genomics at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 2Laboratory of Vascular Biology,
Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China, 3Shanghai Key Laboratory of Vascular Biology,
Shanghai Institute of Hypertension, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 4Department of Epidemiology, Beijing An Zhen Hospital, Beijing
Institute of Heart, Lung and Blood Vessel Diseases, Capital Medical University, Beijing, China
Abstract
Background: Numerous individually underpowered association studies have been conducted on endothelial nitric oxide
synthase (eNOS) genetic variants across different ethnic populations, however, the results are often irreproducible. We
therefore aimed to meta-analyze three eNOS widely-evaluated polymorphisms, G894T (rs1799983) in exon 7, 4b/a in intron
4, and T2786C (rs2070744) in promoter region, in association with hypertension from both English and Chinese
publications, while addressing between-study heterogeneity and publication bias.
Methods: Data were analyzed using Stata software (version 11.0), and random-effects model was applied irrespective of
between-study heterogeneity, which was evaluated by subgroup and meta-regression analyses. Publication bias was
weighed using the Egger’s test and funnel plot.
Results: There were total 19284/26003 cases/controls for G894T, and 6890/6858 for 4b/a, and 5346/6392 for T2786C
polymorphism. Overall comparison of allele 894T with 894G in all study populations yielded a 16% increased risk for
hypertension (odds ratio [OR]=1.16; 95% confidence interval [95% CI]: 1.07–1.27; P=0.001), and particularly a 32%
increased risk (95% CI: 1.16–1.52; P,0.0005) in Asians and a 40% increased risk (95% CI: 1.19–1.65; P,0.0005) in Chinese.
Further subgroup analyses suggested that published languages accounted for the heterogeneity for G894T polymorphism.
The overall OR of allele 4a versus 4b was 1.29 (95% CI: 1.13–1.46; P,0.0005) in all study populations, and this estimate was
potentiated in Asians (OR=1.42; 95% CI: 1.16–1.72; P,0.0005). For T2786C, ethnicity-stratified analyses suggested a
significantly increased risk for 2786C allele (OR=1.25; 95% CI: 1.06–1.47; P=0.007) and 2786CC genotype (OR=1.69; 95%
CI: 1.20–2.38; P=0.003) in Whites. As an aside, the aforementioned risk estimates reached significance after Bonferroni
correction. Finally, meta-regression analysis on other study-level covariates failed to provide any significance for all
polymorphisms.
Conclusion: We, via a comprehensive meta-analysis, ascertained the role of eNOS G894T and 4b/a polymorphisms on
hypertension in Asians, and T2786C polymorphism in Whites.
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Introduction
Hereditary factors contributed directly to the occurrence of
hypertension, as evidenced by family studies showing that
premature onset of hypertension among first-degree relatives
yielded a remarkable high risk of 3.8 times to develop this disorder
[1]. However, it remains unclear how many genes or which
genetic determinants might constitute such hereditary background
[2]. The gene encoding endothelial nitric oxide synthase (protein:
eNOS; gene: eNOS) is regarded as one of the potentially logical
candidate for hypertension, since its enhanced production or
enzyme bioavailability can lead to the constitutive release of nitric
oxide in endothelial cells, which exerts vasoprotective effects in
blood pressure (BP) regulation [3].
The eNOS spans 21 kb with 26 exons on chromosome 7q35-36.
The biological candidacy of eNOS in hypertension has been well-
defined. For example, knockout mice deficient in eNOS developed
hypertension as adults [4], and contrastingly induction of eNOS
cDNA in mice reduced BP [5]. Since the genomic sequence of eNOS
is highly polymorphic, it is of added interest to confirm which
polymorphism(s) at eNOS might have functional potentials to affect
the final bioavailability of eNOS, and thus the development of
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have been conducted on eNOS polymorphisms across different
ethnic populations, yet with irreproducible and inconclusive results.
To derive a more precise estimation, we therefore meta-analyzed
three eNOSwidely-evaluated polymorphisms,G894T(rs1799983)in
exon 7, 4b/a (an insertion-deletion with 4a denoting four tandem
27-bp repeats and 4b five repeats) in intron 4, T2786C (rs2070744)
in promoter region, in association with hypertension from the
English and Chinese-published literature, while addressing be-
tween-study heterogeneity and publication bias.
Methods
Literature Search
Publications were identified from two international searching
engines, viz. PubMed and Excerpta Medica Database (EMBASE),
as well as two Chinese searching engines, viz. Wanfang database
(http://www.wanfangdata.com.cn) and China Biological Medicine
(CBM) (http://sinomed.imicams.ac.cn/index.jsp) as of Dec. 31,
2010. As a prerequisite, we restricted the search spectrum to articles
written in English or Chinese language, and studies in human
subjects. Boolean combinations of the key subjects (hypertension
OR blood pressure) AND (endothelial nitric oxide synthase OR
nitric oxide synthase 3 OR eNOS OR NOS3 OR ECNOS) AND
(allele OR genotype OR polymorphism OR variant OR variation)
wereused foridentification.Thefull textoftheretrievedarticles was
scrutinized to inspect whether data on the topic of interest were
included. Also, reference lists of the retrieved articles and systematic
reviews were checked to determine whether citations of articles that
were not initially identified. If more than one geographical or ethnic
populations were included in one report, each population was
treated separately.
Inclusion/Exclusion Criteria
Identified studies satisfied the following criteria: (i) evaluation of
eNOS G894T or 4b/a or T2786C polymorphism in association
with hypertension; (ii) case-control or nested case-control or cross-
sectional study; (iii) genotype/allele counts of G894T, 4b/a and
T2786C polymorphisms between cases and controls for estimat-
ing odds ratio (OR) and 95% confidence interval (95% CI).
Hypertension was defined as systolic BP equal to or above 140
mmHg or diastolic BP equal to or above 90 mmHg or treatment
with antihypertensive medication. Moreover, gestational hyper-
tension studies were also included. However, studies evaluating
secondary hypertension or other types of monogenic hypertension
were excluded. If two or more studies shared the whole or part of
study populations, the one with larger sample size was recruited.
Extracted Information
Two authors (W. Niu and Y. Qi) independently drew the
following information from all qualified studies: first author’s last
name, publication date, population ethnicity, diagnosis criteria for
BP, study design, baseline characteristics of the study population,
and the genotype distribution in patients and controls. Any
encountered discrepancies were adjudicated by a discussion until a
consensus was reached.
For consistency, continuous variables expressed as mean 6
standard error (SE) were converted to mean 6 standard deviation
(SD). Moreover, the units of measures used in this study are
transformed into the standard measurement units.
Statistical Analysis
Overall allelic/genotypic associations of eNOS G894T, 4b/a and
T2786C polymorphisms with hypertension were calculated using
the Stata software version 11.0 for Windows. In this meta-analysis,
we implemented the random-effects model using the method of
DerSimonian & Laird, instead of fixed-effects model, to bring the
individual effect-size estimates together, and the estimate of
heterogeneity was taken from the Mantel-Haenszel model [6].
Heterogeneity was assessed by the I
2 statistic, which was
documented for the percentage of the observed between-study
variability due to heterogeneity rather than chance with the ranges
of 0 to 100% [I
2=0–25%, no heterogeneity; I
2=25–50%,
moderate heterogeneity; I
2=50–75%, large heterogeneity;
I
2=75–100%, extreme heterogeneity] [7].
In addition, to look at more narrowly drawn subsets of the
studies such as different study designs, separate analyses were
undertaken in a sensitivity manner. Furthermore, to estimate the
extent to which one or more covariates explain heterogeneity,
meta-regression, as an extension to random-effects meta-analysis,
was employed.
Finally, publication bias was assessed using the Egger regression
asymmetry test. The Egger’s test detects funnel plot asymmetry by
determining whether the intercept deviates significantly from zero
in a regression of the standardized effect estimates against their
precision.
A naı ¨ve probability of less than 0.05 was judged significant, and
Bonferroni correction was used to control for the multiple testing
in view of three polymorphisms under investigation (significance
was set at 0.05/3). Because the inconsistency index I
2 test and
Egger’s test are recognized to have poor power, it is recommended
that these statistics were statistically significant if the probability
was less than 0.1 [7].
Results
Description of Available Studies
According to our search strategies, total 115 written-in-English
(WIE) studies and 108 written-in-Chinese (WIC) studies were
initially identified. Further application of our inclusion/exclusion
criteria left 41 WIE (43 populations) [8–48] and 33 WIC (34
populations) (See Table S1: Chinese references 1–33) studies.
Thereof, 32 WIE and 23 WIC studies were qualified for G894T
polymorphism, 21 and 12 for 4b/a polymorphism, and 12 and 4
for T2786C polymorphism. As for the sample size, there were
19284 (WIE/WIC: 15498/3783) cases and 26003 (22444/3559)
controls for G894T polymorphism, and 6890 (4763/2127) cases
and 6858 (4816/2042) controls for 4b/a polymorphism, and 5346
(4693/653) cases and 6392 (5956/436) controls for T2786C
polymorphism. The baseline characteristics of all qualified studies
and a diagram schematizing the selection process of identified
studies are presented in Table S1 and Figure 1, respectively.
G894T and Hypertension
Overall comparison of allele 894T with 894G, including both
WIE and WIC studies, yielded an increased hypertension risk
(OR=1.16; 95% CI: 1.07–1.27; P=0.001), even after Bonferroni
correction, yet with strong evidence of heterogeneity (I
2=74.6%,
P,0.0005) and high probability of publication bias as reflected by
asymmetric funnel plot and significant Egger’s test (P=0.006).
The magnitude of risk estimates for G894T genotype compari-
sons, as well as under dominant and recessive models were very
similar to that in allele comparison (Table 1). Analyses by
published language revealed that, whereas in WIC studies, the
894T may be associated with an increased hypertension risk even
after Bonferroni correction (OR=1.52; 95% CI: 1.26–1.83;
P,0.0005), no clear evidence for a role of this variant was
observed in WIE studies (Figure 2). Despite the significance of
eNOS and Hypertension: An Updated Meta-Analysis
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funnel plots (Figure 3A and 3B) and statistical tests (PWIE=0.702
and PWIC=0.171) in each subgroup. Irrespective of published
languages, we observed significant association of 894T with
hypertension among populations of Asian descent (OR=1.32;
95% CI: 1.16–1.52; P,0.0005) and among populations of
Chinese descent (OR=1.40; 95% CI: 1.19–1.65; P,0.0005)
(Figure S1).
In ethnicity-stratified analyses, no significance was reached in
allele model for WIE studies among Asians (OR=1.09; P=0.353),
Arabs (OR=1.66; P=0.435), Whites (OR=0.99; P=0.828) and
Blacks (OR=0.85; P=0.311), whereas contrastingly, the odds of
developing hypertension were remarkably potentiated, albeit
suffering heterogeneity, in WIC studies, except for a Kazakh
study (Figure S2).
Additional stratification by study design showed slightly
increased risk in hospital-based studies compared with popula-
tion-based studies for both WIE and WIC studies, with
significance reached in only WIC studies (Figure S3). After
excluding one study with gestational hypertension, no material
changes were observed from the above estimates.
To investigate the possible sources of heterogeneity, we meta-
regressed the genetic effects of G894T polymorphism on
explanatory variables including averaged levels of age, gender
(male percent), study design, BMI, TG, TC, and HDLC.
Unfortunately, the confounders under study showed no statistical
contribution to the prediction of hypertension in allele/genotype
models for both WIE and WIC studies (data not shown).
4b/a and Hypertension
Considering the funnel plots (Figure 3C and 3D) and statistical
tests, comparisons of allele (PEgger=0.289), genotype (4a/4b versus
4a/4a: PEgger=0.145; 4a/4a versus 4a/4a: PEgger=0.849),
dominant (PEgger=0.213) and recessive (PEgger=0.801) models in
all qualified publications yielded low probability of publication
bias. The significant overall estimate of allele 4a versus 4b was 1.29
(95% CI: 1.13–1.46; P,0.0005) for all studies, 1.21 (95% CI:
1.06–1.38; P=0.005) for WIE studies and 1.47 (95% CI: 1.11–
1.96; P=0.008) for WIC studies, whereas there was strong
evidence of between-study heterogeneity (P,0.005) (Figure 4).
Comparisons of genotype 4a4b with 4b4b and in dominant model
had the similar magnitude with allele model for all, WIE and WIC
studies, whereas the homogeneous genotype and recessive
comparisons were strengthened in only WIE studies (Table 1).
Still, heterogeneity tingled these comparisons (P,0.01). When
analyses were restricted to WIC studies, the significance persisted
for each comparisons, and there was no publication bias, but
significant between-study heterogeneity (Table 1).
Figure 1. Flow diagram of search strategy and study selection.
doi:10.1371/journal.pone.0024266.g001
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heterogeneity. Considering the study power, only those subgroups
with $3 independent populations were reported. Comparison of
allele 4a with 4b was significant, even after Bonferroni correction,
in Asians (OR=1.42; 95% CI: 1.16–1.72; P,0.0005), but not in
Whites (OR=1.14; 95% CI: 0.91–1.44; P=0.261) (Figure S4).
Further stratification by study design consistently presented
significant associations in both population-based studies
(OR=1.25; 95% CI: 1.02–1.53; P=0.032) and hospital-based
studies (OR=1.30; 95% CI: 1.11–1.52; P=0.001) (Figure S5).
When applying Bonferroni correction, only in hospital-based
studies was there significant. In addition, after stratification upon
disease endpoint, 4b/a polymorphism was not significantly
associated with gestational hypertension across all genetic models,
and significance persisted for essential hypertension (Figure S6).
Furthermore in all studies, meta-regression of 4b/a polymorphism
on averaged levels of age, gender (male percent), study design,
BMI, TG, TC, and HDLC failed to identify any significance, even
by published language stratification (data not shown).
T2786C and Hypertension
Besides the suggestive symmetry of funnel plots (Figure 3E and
3F), Egger’s test indicated no publication bias in all studies for
allele (P=0.889), genotype (2786TC versus 2786TT: P=0.737;
2786CC versus 2786TT: P=0.636), dominant (P=0.996) and
recessive (P=0.454) comparisons. Overall comparison of allele
2786C with 2786T showed null association of this polymorphism
with hypertension (OR=1.12; 95% CI: 0.97–1.29; P=0.137),
even in subgroups by language (Figure 5). Similar associations
were identified in genotype, dominant and recessive models
(Table 1). There was no potential heterogeneity for the
homogenous genotype and recessive comparisons (P.0.1). Results
in Chinese populations still showed null associations for all models,
and suffered significant heterogeneity except for homogeneous
genotype and recessive comparisons, and no publication bias was
observed.
Likewise, stratification by study design showed no significance
for all studies, as well as for WIE and WIC studies (Figure S7).
However, subgroup analyses by ethnicity suggested positivity, even
after Bonferroni correction, for 2786C allele (OR=1.25; 95% CI:
1.06–1.47; P=0.007) and 2786CC genotype (OR=1.69; 95%
CI: 1.20–2.38; P=0.003) with increased hypertension risk in
Whites, even for the dominant and recessive models. Additionally,
we meta-regressed T2786C polymorphism on averaged levels of
age, gender (male percent), study design, BMI, TG, TC, and
HDLC, and found no significant associations at all (data not
shown).
Discussion
Although our overall association produced significance for eNOS
G894T and 4ab polymorphisms in Asians and T2786C
polymorphism in Whites, the indications of between-study
heterogeneity and publication bias, albeit disturbing, should merit
serious consideration. To the best of our knowledge, this is the
largest meta-analysis so far to investigate the association of eNOS
three common polymorphisms with hypertension from the English
and Chinese-published literature.
To avoid the disturbance of publication bias, we divided studies
into characteristic-homogeneous groups such as the published
Table 1. Comparisons of three studied eNOS polymorphisms in allele, genotype dominant and recessive models for hypertension
risk.
Models OR; 95% CI; P; I
2
G894T 4b/a T-786C
All studies
m vs. M 1.16; 1.07–1.27; 0.001; 74.6%
* 1.29; 1.13–1.46; ,0.0005; 60.6%
* 1.12; 0.97–1.29; 0.137; 59.4%
*
mM vs. MM 1.11; 1.00–1.22; 0.044; 67.1%
* 1.32; 1.16–1.51; ,0.0005; 51.7%
* 1.11; 0.94–1.30; 0.224; 52.3%
*
mm vs. MM 1.18; 1.01–1.39; 0.041; 37.1%
* 1.34; 1.01–1.79; 0.045; 11.8% 1.07; 0.82–1.40; 0.610; 21.3%
mM plus mm vs. MM 1.15; 1.04–1.27; 0.005; 71.5%
* 1.33; 1.16–1.52; ,0.0005; 57.3%
* 1.14; 0.98–1.36; 0.142; 58.0%
*
mm vs. mM plus MM 1.20; 1.04–1.38; 0.015; 30.3%
* 1.28; 0.98–1.67; 0.069; 3.3% 1.09; 0.87–1.36; 0.457; 6.3%
Written-in-English Studies
m vs. M 1.01; 0.93–1.10; 0.748; 64.4%
* 1.21; 1.06–1.96; 0.005; 52.8%
* 1.08; 0.94–1.25; 0.255; 54.2%
*
mM vs. MM 0.98; 0.88–1.08; 0.627; 61.7% 1.19; 1.05–1.36; 0.009; 35.2%
* 1.09; 0.94–1.25; 0.247; 32.7%
mm vs. MM 1.03; 0.88–1.19; 0.742; 21.4% 1.44; 1.05–1.40; 0.006; 46.4%
* 1.08; 0.77–1.52; 0.656; 40.3%
*
mM plus mm vs. MM 1.00; 0.90–1.10; 0.932; 63.5%
* 1.22; 1.05–1.40; 0.006; 46.4%
* 1.10; 0.94–1.30; 0.235; 46.3%
*
mm vs. mM plus MM 1.05; 0.95–1.15; 0.345; 0.0% 1.38; 1.03–1.86; 0.032; 0.0% 1.07; 0.80–1.43; 0.656; 31.7%
Written-in-Chinese Studies
m vs. M 1.52; 1.26–1.83; ,0.0005; 70.9%
* 1.47; 1.11–1.96; 0.008; 68.8%
* 1.46; 0.83–2.58; 0.189; 75.4%
*
mM vs. MM 1.43; 1.17–1.74; ,0.0005; 60.2%
* 1.67; 1.25–2.22; ,0.0005; 59.7%
* 1.61; 0.74–3.48; 0.226; 79.2%
*
mm vs. MM 1.94; 1.35–2.77; ,0.0005; 28.4% 1.17; 0.60–2.28; 0.649; 25.8% 0.92; 0.52–1.62; 0.777; 0.0%
mM plus mm vs. MM 1.53; 1.25–1.88; ,0.0005; 66.1%
* 1.60; 1.19–2.16; 0.002; 65.7%
* 1.56; 0.78–3.14; 0.207; 78.3%
*
mm vs. mM plus MM 1.78; 1.30–2.44; ,0.0005; 26.4% 1.06; 0.57–1.98; 0.853; 18.6% 1.01; 0.58–1.75; 0.968; 0.0%
Abbreviations: M, major or wild allele; m, minor or mutant allele; OR, odds ratio; 95% CI, 95% confidence interval.
For G894T, 4b/a and T-786C polymorphisms, the mutant alleles were 894T, 4a and -786C, respectively.
*P ,0.1 for between-study heterogeneity test.
doi:10.1371/journal.pone.0024266.t001
eNOS and Hypertension: An Updated Meta-Analysis
PLoS ONE | www.plosone.org 4 September 2011 | Volume 6 | Issue 9 | e24266Figure 2. Allele comparison of eNOS G894T polymorphism for hypertension by language stratification.
doi:10.1371/journal.pone.0024266.g002
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example, association of G894T polymorphism with hypertension
showed high probability of publication bias in overall analyses,
whereas none was observed in published language-stratified
subgroups. At this point, we interestingly found remarkable
heterogeneous associations by showing null association of 894T
allele with hypertension in WIE studies, which was consistent with
the results of two previous meta-analyses [49,50]. Contrastingly, in
this study, 894T allele carriers had a 52% increased risk in WIC
studies, and a 40% and 32% increased risk, while suffering
significant heterogeneity and publication bias, in Chinese and
Asian populations, respectively (Figure S1). However, this
association exhibited no significance in Whites, suggesting the
heterogeneous associations of G894T polymorphism in ethnicity-
specific populations. In view of this divergence, it is highly
suggested to construct a database of polymorphisms related to
hypertension in each racial or ethnic group [51].
Although linkage information was lacking for eNOS, two
previous powerful meta-analyses indicated positive signals between
eNOS variation and hypertension by consistently predisposing 4b
allele to an increased risk, although publication bias obscured each
study [49,50], which was in agreement with our overall estimates.
Although the influence of publication bias was ‘artificially’ curbed
in this study, existence of heterogeneity still toggled most
comparisons. In ethnicity-stratified analysis, we found striking
heterogeneity by showing 4a allele carriers were at increased
hypertension risk in Asians, but not in Whites. Because 4b/a
polymorphism is intronic, it is unlikely to be functional but might
act as a marker in linkage disequilibrium with other functional
polymorphisms in eNOS regulatory regions. On the other hand,
4b/a might interact with other polymorphisms to predisposing
individuals to susceptibility or resistance to hypertension. As
evidenced, Sandrim et al evaluated the eNOS haplotypes-based risk
and demonstrated the haplotype 2786C-4b-894G was linked to a
protective effect on hypertension risk [52]. Likewise, our recent
haplotype analyses also supported the potential interaction
between polymorphisms 4b/a and T2786C [42]. However,
whether this interaction affects production or bioavailability of
eNOS remains an open question.
As indicated by the results of previous meta-analyses [49,50]
and the present study, the eNOS T2786C polymorphism might
not be a predisposing marker for hypertension. However, we
extended this finding by showing significant association of
T2786C in Whites. Factually, experimental studies have con-
firmed a functional role of this polymorphism on eNOS
transcription activity by showing that the 2786C-4b combination
had the highest transcriptional activity [53]. Herein, because the
single-locus-based nature of meta-analysis precluded the possibility
of gene-gene and gene-environment interactions, as well as
haplotype-based effects in this study, it is highly suggested that
additional studies assessing these aspects will be necessary.
To seek explanations for heterogeneity, besides subgroup
analyses, an alternative approach is to perform a multivariate
meta-analysis, in the form of a meta-regression, with the inclusion
of covariates within this framework. This approach enables the
moderating effect of a covariate, such as age or gender, to be tested
formally. Unfortunately in this study, performing random-effects
meta-regression analyses on various study-level covariates failed to
provide any significant findings for all polymorphisms under study.
However, it is important to bear in mind that meta-regression,
although enabling covariates to be considered, does not have the
methodological rigor of a properly designed study that is intended
to test the effect of these covariates formally [54]. Admittedly, one
limitation facing this study was the number of studies that are
Figure 3. Funnel plots of allele comparisons for eNOS three polymorphisms upon stratification by published language. Vertical axis
represents the log of OR; horizontal axis represents the SE of log(OR). Funnel plots are drawn with 95% confidence limits. OR, odds ratio; SE, standard
error. The graphic symbols represents the data in the plot be sized proportional to the inverse variance.
doi:10.1371/journal.pone.0024266.g003
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study-level covariates of interest, precluding a more robust
assessment of sources of heterogeneity.
Despite the clear strengths of our study including large sample
sizes and comprehensive evaluation of eNOS variation, some
limitations merit serious consideration. First, all included studies
had the cross-sectional design, which precludes further comments
on cause-effect relationship [55]. Second, for hypertension
association studies, most studies have recruited subjects aged
$50 years, for whom environmental factors are likely to
contribute more prominently than the genetic component to the
development of hypertension, suggesting that large association
studies in a younger hypertensive subjects are of added interest.
Third, we cannot retrieve common information from all these
original publications upon some important intermediate pheno-
types such as dietary salt intake in meta-regression models. Last
but not least, in this study, we only focused on eNOS
polymorphisms, and did not evaluate other genes or polymor-
phisms. It is possible that the potential roles of G894T or 4b/a or
T2786C polymorphisms are diluted or masked by other gene-
gene or gene-environment interactions. Thus, the jury must
refrain from drawing a conclusion until a large, well-performed
Chinese study confirms or refuses our results.
Taken together, via a comprehensive meta-analysis, we once
again ascertained the role of eNOS G894T and 4b/a polymor-
phisms on the development of hypertension for Asian populations
and T2786C polymorphism for Whites. Although the publication
bias was maximally avoided, presence of between-study heteroge-
neity could not be fully explained by our subgroup and meta-
regression analyses. Although further analyses are warranted to
Figure 4. Allele comparison of eNOS 4b/a polymorphism for hypertension by language stratification.
doi:10.1371/journal.pone.0024266.g004
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studies should center on gene-gene and gene-environment
interactions, as well as haplotype patterns.
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